|
⚲
|
| Keyboard |
| Blackstone Life Sciences Advisors LLC
✚
|
|
|---|---|
| CRD # | 304477 |
| SEC # | 801-116920 |
| CIK # | |
| AUM | 13.2 B (2026-03-30) |
| Employees | 31 (68% Investors, 0% Brokers) |
| Phone | 617-949-2200 |
| Address | 314 Main Street Cambridge, MA 02142 |
| Source | [IAPD] [Website] [Twitter] [LinkedIn] [Facebook] [Instagram] |
| Total AUM ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Blackstone Life Sciences VI - BL LP | [2026-03-30] | 3.6 B | 88.2 M |
| Filed 2025-11-20 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Blackstone Life Sciences VI - B LP | [2026-03-30] | 3.6 B | 163.0 M |
| Filed 2025-11-20 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Blackstone Life Sciences VI LP | [2025-03-28] | 3.6 B | 3.8 B |
| Filed 2025-12-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $22,925,000 · Revenue Decline to Disclose | ||||
| PE | Blackstone Life Sciences VI Lux SCSP | [2025-03-28] | 3.6 B | 372.8 M |
| Filed 2025-12-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| Other | Blackstone Life Sciences Yield LP | [2022-03-31] | 1.6 B | 376.5 M |
| Offered $1,642,407,000 · Filed 2022-04-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| Other | Blackstone Life Sciences Yield NT LP | [2022-03-31] | 1.6 B | 859.4 M |
| Offered $1,642,407,000 · Filed 2022-04-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| Other | Blackstone Life Sciences Yield T LP | [2022-03-31] | 1.6 B | 383.2 M |
| Offered $1,642,407,000 · Filed 2022-04-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Blackstone Life Sciences V LP | [2020-01-30] | 4.6 B | 6.6 B |
| Offered $4,605,000,000 · Filed 2020-07-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Commission $18,161,065 · Revenue Decline to Disclose | ||||
| PE | Blackstone Life Sciences V Lux SCSP | [2020-01-30] | 4.6 B | 587.4 M |
| Offered $4,605,000,000 · Filed 2020-07-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 11 | 13.2 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 11 | 13.2 |
| By Discretionary | ||
| Discretionary | 11 | 13.2 |
| Non-Discretionary | 0 | 0.0 |
| Total | 11 | 13.2 |
| By Non-United States Persons | ||
| Non-United States Persons | 2.2 | |
| United States Persons | 11.0 | |
| Total | 11 | 13.2 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| John Finley | Executive Officer | 283 | 16 | |
| Christopher Striano | Executive Officer | 234 | 13 | |
| Matthew Skurbe | Executive Officer | 146 | 13 | |
| Eric Liaw | Executive Officer | 110 | 9 | |
| Omar Rehman | Executive Officer | 153 | 7 | |
| Christopher Placca | Executive Officer | 63 | 6 | |
| Joseph Baratta | Executive Officer | 117 | 5 | |
| Nentcho Nentchev | Executive Officer | 71 | 5 | |
| Tabea Hsi | Executive Officer | 9 | 5 | |
| Nicholas Galakatos | Executive Officer | 53 | 3 | |
| Robert Liptak | Executive Officer | 23 | 3 | |
| Ilan Halal | Executive Officer | 19 | 3 | |
| Bxls V LLC | Promoter | 11 | 2 | |
| Blackstone Life Sciences Associates V LP | Promoter | 11 | 2 | |
| Chris Placca | Executive Officer | 9 | 2 | |
| Elsa Gelin | Executive Officer | 8 | 2 | |
| Julie Constable | Executive Officer | 8 | 2 | |
| Nick Galakatos | Executive Officer | 8 | 2 | |
| Natacha Jamar | Executive Officer | 6 | 2 | |
| Victoria Portnoy | Executive Officer | 6 | 2 | |
| Alicia Novak | Executive Officer | 4 | 1 | |
| Blackstone Life Sciences Associates VI LP | Promoter | 4 | 1 | |
| Bxls VI LLC | Promoter | 4 | 1 | |
| Mathias Favetto | Executive Officer | 4 | 1 | |
| Bxls Yield LLC | Promoter | 3 | 1 | |
| Blackstone Life Sciences Yield Associates LP | Promoter | 3 | 1 | |
| Blackstone Life Sciences Associates V Lux S RL | Promoter | 1 | 1 | |
| Blackstone Life Sciences Associates VI Lux Sa RL | Promoter | 1 | 1 | |
| John Finey | Executive Officer | 1 | 1 | |
| Blackstone Life Sciences Associates V Lux Sa RL | Promoter | 1 | 1 |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Private Equity |
| LEI | 9845005B5BIB1AB71B18 |
| Related Firms | State | AUM |
|---|---|---|
|
Blackstone Life Sciences Advisors LLC
✚
|
MA | 13.2 B |
|
Clarus Ventures LLC
✚
|
MA | 805.6 M |
| Comparable Firms | State | AUM |
|---|---|---|
|
JMI Management LP
✚
|
MD | 13.6 B |
|
ArcLight Capital Partners LLC
✚
|
MA | 13.5 B |
|
Partners Enterprise Capital LLC
✚
|
IL | 13.5 B |
|
STG Partners LLC
✚
|
CA | 13.4 B |
|
Eight Partners VC LLC
✚
|
TX | 13.4 B |
|
PCP Managers LP
✚
|
CA | 13.4 B |
|
Asia Alternatives Management LLC
✚
|
CA | 13.2 B |
|
Novacap Management Inc
✚
|
13.2 B | |
|
EMG Fund II Management LP
✚
|
TX | 13.1 B |
|
Impresa Management LLC
✚
|
MA | 13.0 B |